Last reviewed · How we verify
Empagliflozin and Linagliptin
At a glance
| Generic name | Empagliflozin and Linagliptin |
|---|---|
| Also known as | Jardiance, Trajenta |
| Sponsor | Institut für Pharmakologie und Präventive Medizin |
| Drug class | Dipeptidyl Peptidase 4 Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Urinary tract infection
- Female genital mycotic infections
- Nasopharyngitis
- Upper respiratory tract infection
- Dyslipidemia
- Increased urination
- Male genital mycotic infections
- Diarrhea
- Arthralgia
- Nausea
- Cough
- Thirst/Polydipsia
Serious adverse events
- Pancreatitis
- Hypotension
- Syncope
- Hypersensitivity/Angioedema
- Urticaria
- Bronchial hyperreactivity
- Myalgia
Key clinical trials
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes (PHASE4)
- Glycemic Variability of Combination Therapies in T2DM (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes (NA)
- Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus (PHASE3)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients . (PHASE4)
- Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: